Review· rodentsmedium
2026
Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.
This review suggests that BPC 157 may serve as a cytoprotective mediator to counteract both hemorrhage and thrombosis, and promote wound healing and arrhythmia control. The paper concludes that BPC 157 has a unique ability to provide full cytoprotective effects, unlike conventional agents which offer only partial protection.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Barisic I et al.
PubMed · PMID 41901308 ↗Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.
This review concludes that BPC-157 has therapeutic potential in addressing electrolyte imbalances, including hyperkalemia, hypokalemia, hypermagnesemia, and hyperlithiemia, by counteracting adverse effects and promoting recovery. The peptide demonstrated comprehensive counteractive effects in various studies, including in vitro and in vivo experiments.
Current neuropharmacology· Grubisic MM, Strbe S et al.
PubMed · PMID 41832718 ↗Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.
This review concludes that BPC 157, a stable gastric pentadecapeptide, shows promise in treating complex musculoskeletal and junctional injuries, with efficacy in tendon, ligament, and muscle healing. BPC 157 appears to have a full cytoprotection range and can be administered systemically or locally without a carrier.
Pharmaceuticals (Basel, Switzerland)· Matek D, Matek I et al.
PubMed · PMID 41754849 ↗Animal study· ratmedium
2026
Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.
This study found that BPC 157 therapy produced rapid molecular changes in the aortic wall of rats after unilateral adrenalectomy, leading to a more structurally stable and functionally favorable state. The changes were observed through Fourier transform infrared spectroscopy and suggest early extracellular matrix reinforcement and membrane preservation.
Pharmaceuticals (Basel, Switzerland)· Smoday IM, Vukovic V et al.
PubMed · PMID 41599787 ↗Animal study· ratmedium
2026
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.
BPC-157 therapy was shown to rapidly reverse tracheocutaneous fistula in rats by acting through the NO system, leading to healing of skin and tracheal defects and fistula closure. The therapy also counteracted the negative effects of NO system blockade and immobilization.
Pharmaceuticals (Basel, Switzerland)· Madzarac G, Becejac T et al.
PubMed · PMID 41599743 ↗Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy.
This review introduces a novel conceptual framework for evaluating corneal ulcer therapy and highlights the potential of BPC-157 as a cytoprotective agent in promoting healing and reducing complications. The framework also suggests that BPC-157 may have benefits in treating glaucoma and promoting tendon healing.
Pharmaceuticals (Basel, Switzerland)· Masnec S, Kokot A et al.
PubMed · PMID 41471311 ↗Mechanistic· mouse, ratmedium
2025
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.
BPC-157 therapy targets angiogenesis and nitric oxide's cytotoxic actions while maintaining their essential protective functions, and exhibits anti-tumor potential and counteracts neurodegenerative diseases in animal models. The paper defends BPC-157's safety and efficacy against speculation of negative impacts.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Seiwerth S et al.
PubMed · PMID 41155565 ↗Review· mouse, ratmedium
2025
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.
This review concludes that BPC-157 has pleiotropic beneficial effects, controlling and modulating angiogenesis and the NO-system, and shows promise in wound healing and counteracting neurodegenerative diseases. BPC-157 also exhibits anti-tumor potential and does not produce corneal neovascularization.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Seiwerth S et al.
PubMed · PMID 40573323 ↗Animal study· ratmedium
2025
Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury.
This study found that BPC-157 had a significant protective effect against distant organ damage in the liver, kidneys, and lungs following lower extremity ischemia-reperfusion injury in rats. The treatment reduced histopathological damage and increased antioxidant activity in these organs.
Medicina (Kaunas, Lithuania)· Demirtaş H, Özer A et al.
PubMed · PMID 40005408 ↗Animal study· ratmedium
2025
Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats.
This study found that BPC-157 therapy promoted muscle-to-bone reattachment and restored muscle function in rats with detached quadriceps muscles. The therapy showed consistent healing effects at various time points, leading to well-organized bone formation and mature muscle fibers.
Pharmaceutics· Matek D, Matek I et al.
PubMed · PMID 39861766 ↗Human trial· humanmedium
2024
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
This pilot study found that a single injection of BPC-157 around the area of inflammation in the bladder resulted in complete resolution of symptoms in 10 out of 12 patients with moderate to severe interstitial cystitis who did not respond to pentosan polysulfate treatment. The remaining 2 patients reported significant improvement, with 80% of their symptoms resolved.
Alternative therapies in health and medicine· Lee E, Walker C et al.
PubMed · PMID 39325560 ↗Animal study· ratmedium
2024
Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
The study found that BPC-157, a stable gastric pentadecapeptide, rapidly induces vessel recruitment and healing in rats with duodenocolic fistulas, leading to closed defects and resolved leakage. All BPC-157-treated rats showed significant improvement, with no fistula leakage, diarrhea, or weight loss, and reduced adhesion formation and intestinal obstruction.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Vukusic D, Zenko Sever A et al.
PubMed · PMID 38583442 ↗Animal study· ratmedium
2023
Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.
BPC-157 therapy was shown to effectively counteract reperfusion-induced occlusion syndrome and reduce organ lesions and thrombosis in rats with severe intra-abdominal hypertension. The therapy also promoted vascular recovery and reversed previous ischemia-course lesions.
Pharmaceuticals (Basel, Switzerland)· Tepes M, Krezic I et al.
PubMed · PMID 38004420 ↗Animal study· ratmedium
2023
Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats.
This study found that BPC-157 therapy can resolve post-embolization syndrome in rats by activating collateral pathways and counteracting multiorgan failure. The therapy rapidly reversed the symptoms of the syndrome, including prime lung lesions and thromboemboli occluding lung vessels.
Pharmaceuticals (Basel, Switzerland)· Smoday IM, Krezic I et al.
PubMed · PMID 37895979 ↗Animal study· ratmedium
2023
Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect.
This study found that BPC-157 therapy can counteract the severe occlusion/occlusion-like syndrome induced by stomach perforation in rats, reducing vascular and multiorgan failure. BPC-157 therapy also promoted healing of the perforated defect and reduced lesions in various organs.
World journal of gastroenterology· Kalogjera L, Krezic I et al.
PubMed · PMID 37545637 ↗Animal study· ratmedium
2023
Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions.
This study found that BPC-157 therapy normalized intraocular pressure and recovered retinal integrity in glaucomatous rats. BPC-157 also showed potential in treating other ocular conditions such as retinal ischemia and corneal injuries.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Kokot A et al.
PubMed · PMID 37513963 ↗Animal study· ratmedium
2023
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy.
This study found that BPC-157 therapy effectively counteracted the severe occlusion/occlusion-like syndrome induced by the antiarrhythmic sotalol in rats, eliminating or attenuating various symptoms such as heart dilatation, thrombosis, and organ congestion. BPC-157 therapy showed promise in preventing and responding to such events.
Pharmaceuticals (Basel, Switzerland)· Premuzic Mestrovic I, Smoday IM et al.
PubMed · PMID 37513889 ↗Animal study· ratmedium
2023
Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy.
The study found that BPC-157 therapy alleviated severe vascular and multiorgan failure syndrome induced by neuroleptics, domperidone, and amphetamine in rats. BPC-157 resolved severe lesions in various organs, including the brain, heart, and lung, and attenuated or eliminated hypertension and thrombosis.
Pharmaceuticals (Basel, Switzerland)· Strbe S, Smoday IM et al.
PubMed · PMID 37375736 ↗Animal study· rat, dogmedium
2022
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.
This study found that BPC-157 has a short elimination half-life and is rapidly metabolized into small peptide fragments in rats and dogs. The results provide the first analysis of the pharmacokinetics of BPC-157, which will be helpful for its translation in the clinic.
Frontiers in pharmacology· He L, Feng D et al.
PubMed · PMID 36588717 ↗Animal study· ratmedium
2022
Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157.
This study found that BPC-157 therapy changed the lipid contents and protein secondary structure conformation in rat blood vessels, with a rapid effect on vessels within a short time upon application, suggesting a protective effect against cell death. The study used Fourier transform infrared spectroscopy to analyze the molecular changes in the blood vessels.
Biomedicines· Gamulin O, Oroz K et al.
PubMed · PMID 36551886 ↗Mechanistic· mousemedium
2022
Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro.
BPC-157 reduced radiation-induced liver injury and lipid accumulation in mice and liver cells by upregulating Kruppel-like factor 4. The protective effect of BPC-157 was abolished when KLF4 was knocked down, indicating that KLF4 mediates the protective effect.
Life sciences· Huang BS, Huang SC et al.
PubMed · PMID 36228773 ↗Animal study· ratmedium
2022
BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia.
BPC-157 counteracted ketamine-induced symptoms resembling schizophrenia in rats, including cognitive dysfunction, social withdrawal, and anhedonia, and had an anxiolytic effect. The peptide also affected gene expression in brain tissue, particularly when administered after ketamine.
Biomedicines· Zemba Cilic A, Zemba M et al.
PubMed · PMID 35884767 ↗Animal study· ratmedium
2022
Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats.
This study found that the stable gastric pentadecapeptide BPC 157 had a therapeutic effect on acute pancreatitis in rats, reducing inflammation and improving outcomes. The peptide was shown to activate collateral rescuing pathways and reverse vascular failure.
Biomedicines· Smoday IM, Petrovic I et al.
PubMed · PMID 35740321 ↗Animal study· ratmedium
2022
Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy.
This study found that administration of BPC-157 in rats with spinal cord injuries led to rapid and sustained recovery, with reduced hematoma and swelling, and improved tail function. The therapy was effective even when given 4 days after injury and continued for a month.
Current issues in molecular biology· Perovic D, Milavic M et al.
PubMed · PMID 35678659 ↗Animal study· ratmedium
2022
The anti-nociceptive effect of BPC-157 on the incisional pain model in rats.
BPC-157 was found to have a short-term antinociceptive effect in rats with incisional pain, but its effect was limited to a short period after incision and during the initial phase of pain response. The peptide's anti-inflammatory and wound healing effects did not translate to long-term pain relief in this study.
Journal of dental anesthesia and pain medicine· Jung YH, Kim H et al.
PubMed · PMID 35449779 ↗Animal study· ratmedium
2022
Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
This study found that BPC-157 reduced the severity of myocardial infarction induced by isoprenaline in rats, as evidenced by decreased necrosis markers and attenuated gross and histological damage. BPC-157 also counteracted the noxious effects of the NOS-blocker L-NAME and maintained NO system function.
Biomedicines· Barisic I, Balenovic D et al.
PubMed · PMID 35203478 ↗Pentadecapeptide BPC 157 and the central nervous system.
This review discusses the potential therapeutic effects of BPC-157 in the central nervous system, including its ability to counteract stroke, schizophrenia, and spinal cord injury in animal models. The review concludes that BPC-157 may have beneficial effects on various disturbances in the central nervous system.
Neural regeneration research· Vukojevic J, Milavić M et al.
PubMed · PMID 34380875 ↗Animal study· ratmedium
2021
Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-NG-nitro-L-arginine methyl ester worsening.
The study found that BPC-157 rapidly restored blood vessels and reduced bleeding and defect size in rats with perforated stomachs, leading to advanced healing and reduced adhesions. BPC-157 also reversed abnormal values of malondialdehyde and nitric oxide in stomach tissue.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Bilic Z, Gojkovic S et al.
PubMed · PMID 35485358 ↗Animal study· ratmedium
2021
Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.
This study found that BPC-157 therapy normalized intraocular pressure and prevented glaucoma-like features in rats with cauterized episcleral veins. The treatment also preserved ganglion cells, optic nerve, and retinal and choroidal blood vessels.
Biomedicines· Kralj T, Kokot A et al.
PubMed · PMID 35052769 ↗Animal study· ratmedium
2021
Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats.
This study found that BPC-157 therapy reversed the harmful effects of primary abdominal compartment syndrome in rats, improving venous function and reducing inflammation and damage to various organs. The treatment also prevented severe complications such as heart congestion, subendocardial infarction, and brain edema.
Frontiers in pharmacology· Tepes M, Gojkovic S et al.
PubMed · PMID 34966273 ↗Animal study· ratmedium
2021
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats.
This study found that BPC-157 therapy promotes healing and functional recovery of disabled myotendinous junctions in rats, counteracting muscle atrophy and oxidative stress. The treatment led to complete disappearance of defects and restoration of normal muscle presentation in treated rats.
Biomedicines· Japjec M, Horvat Pavlov K et al.
PubMed · PMID 34829776 ↗Animal study· ratmedium
2021
Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157.
This study found that BPC-157 counteracted lithium-induced occlusive-like syndrome in rats, rapidly improving various symptoms such as brain swelling, vessel failure, and thrombosis. BPC-157 therapy also mitigated organ damage and oxidative stress caused by high-dose lithium intoxication.
Biomedicines· Strbe S, Gojkovic S et al.
PubMed · PMID 34829735 ↗Animal study· nullmedium
2021
Robert's Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157.
This study showed that the stable gastric pentadecapeptide BPC 157 counteracted the deficits caused by intragastric administration of alcohol, including gastric lesions, brain swelling, and lesions in various organs. BPC 157 rapidly reversed these effects and improved the collateral blood flow pathway.
Biomedicines· Gojkovic S, Krezic I et al.
PubMed · PMID 34680419 ↗Animal study· ratmedium
2021
Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats.
BPC-157 therapy was shown to heal established vesicovaginal fistulas and counteract stone formation in rats, with significant improvements in epithelization, collagenization, and granulation tissue. The therapy was effective even when initiated with a considerable delay after fistula formation.
Biomedicines· Rasic D, Zenko Sever A et al.
PubMed · PMID 34572392 ↗Animal study· honeybeemedium
2021
Physiological and Immunological Status of Adult Honeybees (Apis mellifera) Fed Sugar Syrup Supplemented with Pentadecapeptide BPC 157.
This study found that feeding honeybees sugar syrup supplemented with BPC-157 led to positive physiological changes and improved immunity. The results suggest a link between BPC-157 administration and enhanced protein digestion in honeybees.
Biology· Tlak Gajger I, Smodiš Škerl MI et al.
PubMed · PMID 34571768 ↗Animal study· ratmedium
2021
Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats.
BPC-157 therapy rapidly reestablished blood flow and counteracted multiorgan dysfunction syndrome in rats with superior mesenteric vein occlusion. The treatment also reduced hypertension, thrombosis, and oxidative stress in various tissues.
Biomedicines· Knezevic M, Gojkovic S et al.
PubMed · PMID 34440233 ↗Animal study· ratmedium
2021
Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal.
This study found that BPC-157 therapy can prevent and reverse monocrotaline-induced pulmonary arterial hypertension in rats. The treatment was effective in counteracting the disease, regardless of whether it was started early or delayed.
Biomedicines· Udovicic M, Sever M et al.
PubMed · PMID 34356886 ↗Animal study· ratmedium
2021
Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157.
This study found that BPC-157 rapidly activated collateral pathways and counteracted hypertension, thrombosis, and organ lesions in rats with occluded superior mesenteric vein and artery. BPC-157 therapy led to rapid recovery in these rats.
Biomedicines· Knezevic M, Gojkovic S et al.
PubMed · PMID 34356860 ↗Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
This review concludes that BPC-157 has potential in wound healing, including skin wounds, burns, and ulcers, by promoting resolution of vessel constriction and clotting. The peptide may also have applications in healing other tissues, including the gastrointestinal tract and blood vessels.
Frontiers in pharmacology· Seiwerth S, Milavic M et al.
PubMed · PMID 34267654 ↗Animal study· ratmedium
2021
BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment.
BPC 157 therapy rapidly attenuates brain swelling and recruits collateral vessels in rats with permanent occlusion of the superior sagittal sinus. The therapy also alleviates various systemic disturbances, including portal and caval hypertension, aortal hypotension, and thrombosis.
Biomedicines· Gojkovic S, Krezic I et al.
PubMed · PMID 34203464 ↗Animal study· ratmedium
2021
BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats.
BPC-157 was found to counteract retinal ischemia induced by L-NAME in rats, with improvements in fundoscopy, histology, and behavioral presentation. The peptide was effective even when administered 48 hours after L-NAME.
Frontiers in pharmacology· Zlatar M, Kokot A et al.
PubMed · PMID 34177567 ↗Animal study· ratmedium
2021
Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension.
BPC-157 therapy was shown to counteract multiple organ dysfunction syndrome in rats with superior mesenteric artery occlusion by rapidly recruiting collateral vessels and attenuating hypertension and thrombosis. This resulted in reduced organ lesions and disturbances in various organs, including the heart, lung, liver, and brain.
Biomedicines· Knezevic M, Gojkovic S et al.
PubMed · PMID 34073625 ↗Animal study· ratmedium
2021
Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.
The pentadecapeptide BPC-157 counteracted L-NAME-induced catalepsy and schizophrenia-like symptoms in rat models, and maintained its counteracting effect even in the presence of NOS-blockade or NO-system-over-stimulation. BPC-157 also directly inhibited L-NAME high dose-induced catalepsy.
Behavioural brain research· Zemba Cilic A, Zemba M et al.
PubMed · PMID 32956773 ↗Animal study· ratmedium
2020
Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats.
The study found that BPC-157 shortened the duration of corneal anesthesia induced by tetracaine and oxybuprocaine in rats. BPC-157 also counteracted the negative effects of these anesthetics on corneal sensitivity and tear production.
Acta clinica Croatica· Mirković I, Kralj T et al.
PubMed · PMID 34177048 ↗Animal study· ratmedium
2020
Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157.
This study found that BPC-157 attenuated gastric mucosal damage caused by Clopidogrel in rats, and reversed the molecular effects of Clopidogrel on gastric mucosa. BPC-157 inhibited gastric mucosa cell ER stress-mediated apoptosis and inflammation, and promoted gastric mucosa angiogenesis.
Drug design, development and therapy· Wu H, Wei M et al.
PubMed · PMID 33376304 ↗Animal study· ratmedium
2020
Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats.
BPC-157 therapy was shown to reduce bowel adhesion formation in rats, and its beneficial effect was maintained even when combined with other agents. The peptide promoted healing with minimal or no adhesion formation.
World journal of gastrointestinal pharmacology and therapeutics· Cesar LB, Gojkovic S et al.
PubMed · PMID 33251034 ↗Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway.
BPC 157 was found to cause concentration-dependent vasodilation in isolated rat aorta, which is mediated by nitric oxide and involves the activation of the Src-Caveolin-1-endothelial nitric oxide synthase pathway. This effect was endothelium-dependent and required the activation of Src and the release of Caveolin-1 from endothelial nitric oxide synthase.
Scientific reports· Hsieh MJ, Lee CH et al.
PubMed · PMID 33051481 ↗Animal study· ratmedium
2020
In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro.
BPC-157 counteracted lidocaine-induced adverse effects in rats, including limb function failure, arrhythmias, and convulsions. BPC-157 also counteracted lidocaine-induced depolarisation of HEK293 cells.
Emergency medicine international· Lozic M, Stambolija V et al.
PubMed · PMID 32566305 ↗Animal study· ratmedium
2020
The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats.
BPC-157 therapy counteracted neural hippocampal damage and achieved full functional recovery in rats with ischemia/reperfusion injuries. The study suggests that BPC-157 may provide a novel therapeutic solution for stroke.
Brain and behavior· Vukojević J, Vrdoljak B et al.
PubMed · PMID 32558293 ↗Animal study· ratmedium
2020
Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion.
BPC-157 was shown to resolve Pringle maneuver-induced damage in rats, both during ischemia and reperfusion, by rapidly recruiting collateral vessels and attenuating haemodynamic disturbances. This resulted in reduced liver and intestinal damage, as well as improved cardiovascular function.
World journal of hepatology· Kolovrat M, Gojkovic S et al.
PubMed · PMID 32547687 ↗Animal study· ratmedium
2020
Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats.
BPC-157 was shown to counteract Budd-Chiari syndrome in rats by rapidly bypassing the suprahepatic occlusion of the inferior caval vein and reducing associated pathology. The treatment also attenuated thrombosis, hypertension, and organ damage.
World journal of gastrointestinal pathophysiology· Gojkovic S, Krezic I et al.
PubMed · PMID 32226643 ↗Animal study· ratmedium
2019
Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot.
BPC-157 counteracted the inhibitory effects of aspirin, clopidogrel, and cilostazol on platelet aggregation in rats. The peptide rescued thrombocyte function without affecting the extrinsic/intrinsic hemostasis system or clotting time.
Oxidative medicine and cellular longevity· Konosic S, Petricevic M et al.
PubMed · PMID 31976029 ↗Animal study· ratmedium
2019
Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME.
This study found that BPC-157 attenuated cyclophosphamide-induced hemorrhagic cystitis in rats, and its effects were not blocked by L-NAME or enhanced by L-arginine. BPC-157 also reversed the increased leak point pressure caused by cyclophosphamide.
European journal of pharmacology· Sucic M, Luetic K et al.
PubMed · PMID 31401154 ↗Animal study· ratmedium
2019
Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats.
This study found that BPC-157 therapy improved the healing course of spinal cord injury in rats, leading to functional recovery and counteracting axonal and neuronal necrosis. The treatment resulted in consistent clinical improvement, including better motor function and resolved spasticity.
Journal of orthopaedic surgery and research· Perovic D, Kolenc D et al.
PubMed · PMID 31266512 ↗Animal study· ratmedium
2019
Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation.
BPC-157 therapy was shown to counteract liver fibrosis and portal hypertension in rats with bile duct ligation, reversing jaundice and normalizing liver tissue values. The peptide also reduced inflammation and improved liver function in the treated rats.
European journal of pharmacology· Sever AZ, Sever M et al.
PubMed · PMID 30690000 ↗Animal study· ratmedium
2018
Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine.
This study found that BPC-157, alone or in combination with L-NAME and L-arginine, promoted healing of perforated cecum lesions in rats by increasing vessel presentation, reducing bleeding, and normalizing MDA and NO levels. The treatment also reduced adhesions and improved defect closure.
World journal of gastroenterology· Drmic D, Samara M et al.
PubMed · PMID 30622376 ↗Animal study· ratmedium
2018
Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine.
This study found that BPC-157, a stable gastric pentadecapeptide, can attenuate duodenal lesions and improve vascular presentation in rats with major venous occlusions, and its effects are related to the nitric oxide system and reduction of free radical formation. BPC-157 also normalized levels of oxidative stress markers in duodenal tissues.
World journal of gastroenterology· Amic F, Drmic D et al.
PubMed · PMID 30598581 ↗Animal study· ratmedium
2018
An endogeous defensive concept, renewed cytoprotection/adaptive cytoprotection: intra(per)-oral/intragastric strong alcohol in rat. Involvement of pentadecapeptide BPC 157 and nitric oxide system.
This study found that the peptide BPC-157 can protect against alcohol-induced stomach ulcers and other gastrointestinal damage in rats, and that the tongue may play a role in initiating this protective effect. The study also suggests that the nitric oxide system is involved in this process.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Becejac T, Cesarec V et al.
PubMed · PMID 30279308 ↗Animal study· honeybeemedium
2018
Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions.
The study found that honeybee colonies fed with sugar syrup supplemented with BPC-157 had increased strength and reduced Nosema ceranae spore loads, and that BPC-157 attenuated damage to the midgut wall layers and epithelial cells in infected honeybees. This suggests that BPC-157 may have therapeutic effects in controlling Nosema ceranae invasions in honeybees.
Journal of veterinary pharmacology and therapeutics· Tlak Gajger I, Ribarić J et al.
PubMed · PMID 29682749 ↗Animal study· ratmedium
2018
Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157.
This study found that BPC-157 therapy attenuated or counteracted the effects of inferior caval vein ligation in rats, including vessel injury, stasis, thrombosis, and hemodynamic changes. BPC-157 also promoted the formation of collateral blood vessels and improved blood flow.
Vascular pharmacology· Vukojević J, Siroglavić M et al.
PubMed · PMID 29510201 ↗Animal study· ratmedium
2017
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights.
BPC-157 treatment restored blood supply to ischemically injured areas in rat models of colitis and ischemia/reperfusion, and rapidly activated collaterals. The treatment also reduced oxidative stress and improved mucosal health in these models.
World journal of gastroenterology· Duzel A, Vlainic J et al.
PubMed · PMID 29358856 ↗Animal study· ratmedium
2017
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME.
This study found that BPC-157 and L-arginine can counteract the negative effects of celecoxib on the gastrointestinal, liver, and brain tissues in rats. BPC-157 was shown to be effective in reducing lesions and liver enzyme serum values caused by celecoxib.
World journal of gastroenterology· Drmic D, Kolenc D et al.
PubMed · PMID 28839430 ↗Animal study· ratmedium
2017
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
This study found that BPC-157 counteracts the QTc interval prolongation induced by several neuroleptics and prokinetics in rats. The peptide rapidly and permanently reversed this effect, suggesting its potential in preventing cardiac complications associated with these medications.
Life sciences· Strinic D, Belosic Halle Z et al.
PubMed · PMID 28797793 ↗Animal study· ratmedium
2017
Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats.
This study found that BPC-157 counteracts the negative effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the lower esophageal and pyloric sphincters in rats. BPC-157 restored normal pressure values in these sphincters after NSAID-induced failure.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Vitaic S, Stupnisek M et al.
PubMed · PMID 28614776 ↗Animal study· ratmedium
2017
Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine.
The study found that BPC-157 counteracts the decrease in lower oesophageal and pyloric sphincter pressure caused by dopamine antagonists, neuroleptics, and other substances. BPC-157 also reversed the negative effects of these substances on NO levels and oxidative stress in the plasma, sphincters, and brain tissue.
Inflammopharmacology· Belosic Halle Z, Vlainic J et al.
PubMed · PMID 28516373 ↗Animal study· ratmedium
2017
Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: L-NAME, L-arginine, stable gastric pentadecapeptide BPC 157.
This study found that BPC-157 therapy attenuated stomach and duodenal ulcers and lesions in rats induced by cyclophosphamide, and also reduced increased NO and MDA levels in these tissues. BPC-157 counteracted the effects of cyclophosphamide and L-NAME on stomach and duodenal lesions.
Inflammopharmacology· Luetic K, Sucic M et al.
PubMed · PMID 28255738 ↗Animal study· ratmedium
2017
Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen.
BPC 157 was shown to counteract hypermagnesemia and magnesium-induced disturbances in rats, while L-NAME and L-arginine worsened these effects. The peptide also inhibited cell depolarization due to increasing magnesium concentration in vitro.
Inflammopharmacology· Medvidovic-Grubisic M, Stambolija V et al.
PubMed · PMID 28210905 ↗Mechanistic· ratmedium
2017
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
BPC-157 promotes angiogenesis by increasing the expression and internalization of VEGFR2, and activating the VEGFR2-Akt-eNOS signaling pathway. This study demonstrates the therapeutic potential of BPC-157 in promoting blood flow recovery and vessel formation in ischemic tissues.
Journal of molecular medicine (Berlin, Germany)· Hsieh MJ, Liu HT et al.
PubMed · PMID 27847966 ↗Animal study· ratmedium
2016
Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME.
BPC-157 treatment improved healing of esophagogastric anastomosis in rats and counteracted the negative effects of L-NAME, while L-arginine also showed beneficial effects. The study suggests that BPC-157 therapy could correct innate NO-system disability in esophagogastric anastomoses.
World journal of gastroenterology· Djakovic Z, Djakovic I et al.
PubMed · PMID 27895400 ↗Animal study· ratmedium
2016
Stable gastric pentadecapeptide BPC 157 and bupivacaine.
BPC 157 was shown to prevent and counteract bupivacaine cardiotoxicity in rats, and its administration was effective even when given after bupivacaine injection. The peptide also inhibited bupivacaine-induced depolarization in HEK293 cells.
European journal of pharmacology· Zivanovic-Posilovic G, Balenovic D et al.
PubMed · PMID 27815173 ↗Animal study· ratmedium
2016
Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats.
This study found that BPC-157 and L-arginine can ameliorate the negative effects of diclofenac and L-NAME on gastrointestinal, liver, and brain lesions, as well as anastomosis healing and intestinal adaptation in short-bowel rats. BPC-157 completely reversed the deterioration caused by massive intestinal resection, diclofenac, and L-NAME.
PloS one· Lojo N, Rasic Z et al.
PubMed · PMID 27627764 ↗Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.
This review concludes that BPC-157, a gastric peptide, may serve as a remedy in various CNS-disorders and has shown beneficial effects in treating GI tract lesions, periodontitis, and liver and pancreas lesions. BPC-157 also has neuroprotective effects and modulates serotonergic and dopaminergic systems.
Current neuropharmacology· Sikiric P, Seiwerth S et al.
PubMed · PMID 27138887 ↗Animal study· ratmedium
2016
BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias.
BPC 157 was shown to counteract the effects of succinylcholine, including hyperkalemia, arrhythmias, and muscle damage, in rats. The peptide mitigated local and systemic disturbances and eliminated hyperkalemia, arrhythmias, and post-succinylcholine hyperalgesia.
European journal of pharmacology· Stambolija V, Stambolija TP et al.
PubMed · PMID 27060013 ↗Animal study· ratmedium
2016
Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula.
BPC-157, a stable gastric pentadecapeptide, was shown to rapidly improve and eventually heal colovesical fistulas in rats. The treatment led to the amelioration of colon and vesical defects, reduction of fistula leakage, and prevention of adhesion formation and intestinal obstruction.
European journal of pharmacology· Grgic T, Grgic D et al.
PubMed · PMID 26875638 ↗Animal study· ratmedium
2016
Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats.
This study found that the peptide BPC-157, given orally or intraperitoneally, rapidly improved and eventually healed rectovaginal fistulas in rats. The treatment also reduced adhesion formation and intestinal obstruction.
Life sciences· Baric M, Sever AZ et al.
PubMed · PMID 26872976 ↗Animal study· rat, guinea pigmedium
2016
NO system dependence of atropine-induced mydriasis and L-NAME- and L-arginine-induced miosis: Reversal by the pentadecapeptide BPC 157 in rats and guinea pigs.
The study found that BPC 157 counteracts atropine-induced mydriasis and modulates the effects of L-NAME and L-arginine on pupil size in rats and guinea pigs. BPC 157 also affects L-arginine-miosis and L-NAME-miosis, suggesting its participation in ocular control via NO-mediated and cholinergic mechanisms.
European journal of pharmacology· Kokot A, Zlatar M et al.
PubMed · PMID 26698393 ↗Animal study· ratmedium
2015
BPC 157 antagonized the general anaesthetic potency of thiopental and reduced prolongation of anaesthesia induced by L-NAME/thiopental combination.
BPC 157 was found to antagonize the general anaesthetic potency of thiopental and reduce the prolongation of anaesthesia induced by the L-NAME/thiopental combination. The study suggests that BPC 157's effects on thiopental anaesthesia are related to NO system activity modulation.
Inflammopharmacology· Zemba M, Cilic AZ et al.
PubMed · PMID 26563892 ↗Animal study· ratmedium
2015
Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine.
This study found that BPC-157, a pentadecapeptide, healed duodenocutaneous fistulas in rats and improved sphincter function, and its effects were related to the nitric oxide system. The study suggests that BPC-157 could be a potential therapy for wound healing and duodenal ulcers.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Skorjanec S, Kokot A et al.
PubMed · PMID 26348082 ↗Animal study· ratmedium
2015
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.
BPC-157 treatment accelerated wound closure and improved healing in a rat model of alkali burn-induced skin injury, and also promoted cell proliferation, migration, and angiogenesis in vitro. The therapeutic mechanism may involve the ERK1/2 signaling pathway.
Drug design, development and therapy· Huang T, Zhang K et al.
PubMed · PMID 25995620 ↗Animal study· ratmedium
2015
Perforating corneal injury in rat and pentadecapeptide BPC 157.
BPC-157 eye drops accelerated the healing process of perforating corneal incisions in rats, leading to rapid regaining of corneal transparency and reduced formation of new vessels. The healing process was complete in 72-96 hours with BPC-157 treatment, compared to poor healing in controls.
Experimental eye research· Masnec S, Kokot A et al.
PubMed · PMID 25912999 ↗Animal study· ratmedium
2015
Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine.
BPC-157 reduced bleeding and thrombocytopenia in rats after amputation, with or without anticoagulants heparin or warfarin. The peptide also counteracted the effects of L-NAME and L-arginine on hemostatic parameters.
PloS one· Stupnisek M, Kokot A et al.
PubMed · PMID 25897838 ↗Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.
BPC 157 increased the expression of growth hormone receptor in tendon fibroblasts, which may enhance the proliferation-promoting effect of growth hormone and contribute to tendon healing. The study found that BPC 157 dose- and time-dependently increased growth hormone receptor expression in tendon fibroblasts.
Molecules (Basel, Switzerland)· Chang CH, Tsai WC et al.
PubMed · PMID 25415472 ↗Animal study· rat, mousemedium
2014
Pentadecapeptide BPC 157 and anaphylactoid reaction in rats and mice after intravenous dextran and white egg administration.
BPC-157 was found to effectively prevent and rescue anaphylactoid reactions in rats and mice caused by dextran and/or white egg application. The peptide showed a stronger effect than chloropyramine and cimetidine, and its effect was not diminished when combined with these medications.
European journal of pharmacology· Duplancic B, Stambolija V et al.
PubMed · PMID 24486708 ↗Animal study· ratmedium
2013
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.
BPC-157 was shown to heal cysteamine-colitis and colon-colon anastomosis, and counteract cuprizone-induced brain injuries and motor disability in rats. This suggests that BPC-157 may be useful in the treatment of inflammatory bowel disease and multiple sclerosis.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Klicek R, Kolenc D et al.
PubMed · PMID 24304574 ↗Animal study· ratmedium
2013
Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats.
BPC-157 improved leak point pressure in rat models of stress urinary incontinence after surgery or injury, and promoted healing of the urethral wall. The treatment also increased markers of muscle and tissue repair in the affected area.
Medical science monitor basic research· Jandric I, Vrcic H et al.
PubMed · PMID 23478678 ↗Animal study· ratmedium
2013
Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157.
The peptide BPC-157 was shown to counteract hyperkalemia-induced disturbances, including arrhythmias and muscular weakness, in rats. BPC-157 also directly affected potassium conductance in cell culture, suggesting a mechanism for its protective effects.
Regulatory peptides· Barisic I, Balenovic D et al.
PubMed · PMID 23327997 ↗Animal study· ratmedium
2013
Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy.
This study found that BPC-157 accelerated the healing of esophagocutaneous fistulas in rats, counteracting the negative effects of L-NAME and promoting the restoration of sphincter pressure and reduction of esophagitis. BPC-157 was effective when given perorally or intraperitoneally, and it reduced fistula leakage and mortality.
European journal of pharmacology· Cesarec V, Becejac T et al.
PubMed · PMID 23220707 ↗Animal study· ratmedium
2012
Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin.
The peptide BPC-157 reduced bleeding time and thrombocytopenia in rats treated with heparin, warfarin, or aspirin after amputation. BPC-157 also improved survival time in heparin-treated rats.
Thrombosis research· Stupnisek M, Franjic S et al.
PubMed · PMID 21840572 ↗Animal study· ratmedium
2011
BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure.
The study found that BPC-157 therapy can counteract the detrimental effects of sphincter failure, esophagitis, and pancreatitis in rats, and that it may also be beneficial for patients with acute pancreatitis who have low sphincter pressure. The results suggest that BPC-157 could potentially cure esophagitis, sphincter failure, and acute pancreatitis.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Petrovic I, Dobric I et al.
PubMed · PMID 22204800 ↗Animal study· ratmedium
2011
Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats.
The study found that BPC-157, a stable gastric pentadecapeptide, counteracted the adverse effects of ibuprofen in rats, including hepatic encephalopathy, gastric lesions, and hepatomegaly. BPC-157 treatment also maintained normal weight gain and prevented behavioral disturbances in the rats.
European journal of pharmacology· Ilic S, Drmic D et al.
PubMed · PMID 21645505 ↗Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
BPC-157, a stable gastric pentadecapeptide, has been shown to have therapeutic effects on various gastrointestinal tract lesions and injuries, including ulcers, esophagitis, and intestinal anastomosis. It also exhibits anti-inflammatory, angiogenic, and neuroprotective properties.
Current pharmaceutical design· Sikiric P, Seiwerth S et al.
PubMed · PMID 21548867 ↗Animal study· ratmedium
2011
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions.
BPC-157 was found to strongly counteract the toxic side effects of diclofenac, including gastrointestinal, liver, and brain lesions, in a rat model. The peptide was effective when given intraperitoneally or per-orally, and may have potential as a therapy to counteract NSAID-induced toxicity.
Life sciences· Ilic S, Drmic D et al.
PubMed · PMID 21295044 ↗The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
BPC-157 was found to accelerate the outgrowth of tendon explants, increase cell survival under stress, and promote the migration of tendon fibroblasts. This is likely mediated by the activation of the FAK-paxillin pathway.
Journal of applied physiology (Bethesda, Md. : 1985)· Chang CH, Tsai WC et al.
PubMed · PMID 21030672 ↗Animal study· ratmedium
2010
High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736).
This study found that BPC-157 can counteract the toxic effects of a high dose of paracetamol in rats, preventing liver damage, brain damage, and generalized convulsions. BPC-157 was effective when given both as a prophylactic and therapeutic treatment.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Ilic S, Drmic D et al.
PubMed · PMID 20436226 ↗Animal study· ratmedium
2010
Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.
The peptide BPC-157 improved healing of medial collateral ligament injuries in rats when given intraperitoneally, locally, or per-orally. The treatment resulted in consistent functional, biomechanical, macroscopic, and histological healing improvements.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society· Cerovecki T, Bojanic I et al.
PubMed · PMID 20225319 ↗Animal study· ratmedium
2010
Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application.
BPC-157 improved muscle healing in rats with muscle crush injury and counteracted the negative effects of corticosteroid treatment on muscle healing. The peptide completely reversed systemic corticosteroid-impaired muscle healing.
Medical science monitor : international medical journal of experimental and clinical research· Pevec D, Novinscak T et al.
PubMed · PMID 20190676 ↗Animal study· mousemedium
2010
Traumatic brain injury in mice and pentadecapeptide BPC 157 effect.
BPC-157 administration reduced the severity of traumatic brain injury in mice, with improved outcomes and reduced mortality. The peptide was effective when given before or after injury, with the timing and dosage depending on the severity of the injury.
Regulatory peptides· Tudor M, Jandric I et al.
PubMed · PMID 19931318 ↗Animal study· ratmedium
2010
Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.
The study found that BPC-157 improved the healing of rat sciatic nerves after injury, with faster axonal regeneration and improved functional recovery. The treatment also reduced autotomy and improved the sciatic functional index.
Regulatory peptides· Gjurasin M, Miklic P et al.
PubMed · PMID 19903499 ↗Animal study· nullmedium
2009
Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.
BPC 157 was found to modulate angiogenesis in muscle and tendon healing by up-regulating VEGF expression, leading to more adequate healing. This effect was observed in animal models of crushed and transected muscle and tendon.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Brcic L, Brcic I et al.
PubMed · PMID 20388964 ↗Animal study· mousemedium
2009
Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice.
The study found that BPC 157 counteracts morphine-induced analgesia in mice, and this effect is related to the central dopaminergic system. BPC 157 also counteracted the enhancement of morphine analgesia by haloperidol, a central dopamine antagonist.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Boban Blagaic A, Turcic P et al.
PubMed · PMID 20388962 ↗Animal study· ratmedium
2009
Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy.
The peptide BPC-157 was shown to decrease clot formation and improve walking ability and muscle strength in rats after aortic anastomosis. When given after anastomosis, BPC-157 rapidly recovered lower limb function and muscle strength.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Hrelec M, Klicek R et al.
PubMed · PMID 20388960 ↗Animal study· ratmedium
2009
Antiinflammatory effect of BPC 157 on experimental periodontitis in rats.
BPC-157 reduced inflammation and bone resorption in a rat model of periodontitis. The peptide had a potent anti-inflammatory effect on periodontal tissues in ligature-induced periodontitis.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Keremi B, Lohinai Z et al.
PubMed · PMID 20388954 ↗Animal study· ratmedium
2009
Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats.
The stable gastric pentadecapeptide BPC 157 was shown to counteract the disturbances and fatal outcome caused by an overdose of insulin in rats, including gastric ulcers, seizures, and liver damage. BPC 157 treatment resulted in improved survival rates, reduced liver pathology, and decreased brain damage.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society· Ilic S, Brcic I et al.
PubMed · PMID 20388953 ↗Animal study· ratmedium
2009
Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system.
BPC-157 was shown to prevent and counteract digitalis-induced arrhythmias in rats, likely through interaction with the NO-system. The peptide reduced the number of ventricular premature beats, prolonged the time before onset of ventricular tachycardia, and shortened AV-block duration.
Regulatory peptides· Balenovic D, Bencic ML et al.
PubMed · PMID 19465062 ↗Animal study· ratmedium
2009
Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats.
Rats with short bowel syndrome that received BPC-157 therapy showed constant weight gain, improved intestinal health, and increased anastomosis breaking strength compared to untreated rats. This suggests that BPC-157 could be helpful in treating short bowel syndrome.
Digestive diseases and sciences· Sever M, Klicek R et al.
PubMed · PMID 19093208 ↗Animal study· ratmedium
2009
Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole.
This study found that BPC-157, a stable gastric pentadecapeptide, was more effective in healing gastrocutaneous fistulas in rats compared to standard anti-ulcer agents. BPC-157 also improved healing of both skin and stomach mucosa, even after corticosteroid aggravation.
Digestive diseases and sciences· Skorjanec S, Dolovski Z et al.
PubMed · PMID 18649140 ↗Animal study· ratmedium
2008
Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.
BPC-157 accelerated the healing of colocutaneous fistulas in rats, and its beneficial effects remained unchanged even when nitric oxide generation was blunted. The peptide also outperformed sulphasalazine and corticosteroids in promoting wound healing.
Journal of pharmacological sciences· Klicek R, Sever M et al.
PubMed · PMID 18818478 ↗Animal study· ratmedium
2008
Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat.
BPC-157 accelerated muscle healing in rats with crush injuries, improving both macroscopic and microscopic outcomes, as well as functional recovery. The peptide was effective when administered locally or intraperitoneally.
Surgery today· Novinscak T, Brcic L et al.
PubMed · PMID 18668315 ↗Animal study· ratmedium
2008
Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone.
This study found that BPC-157 improved functional recovery of the Achilles tendon to bone unit after transection in rats by reducing inflammation and promoting new blood vessel formation. BPC-157 outperformed methylprednisolone in this regard, as it did not suppress new blood vessel formation.
Inflammation research : official journal of the European Histamine Research Society ... [et al.]· Krivic A, Majerovic M et al.
PubMed · PMID 18594781 ↗Animal study· ratmedium
2007
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat.
This study found that BPC-157 improved the healing of ileoileal anastomosis in rats, with benefits including reduced edema, decreased necrosis, and increased collagen formation. The peptide was shown to have a beneficial effect on anastomotic wound healing.
Surgery today· Vuksic T, Zoricic I et al.
PubMed · PMID 17713731 ↗Animal study· ratmedium
2007
Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157.
The study found that BPC-157 alleviated esophagitis and improved sphincter pressure in rats with prolonged esophagitis, while ranitidine had no effect. BPC-157 also increased lower esophageal sphincter pressure in normal rats, but decreased pyloric sphincter pressure.
Journal of pharmacological sciences· Dobric I, Drvis P et al.
PubMed · PMID 17452811 ↗Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.
This review highlights the potential of BPC-157 as a cytoprotective agent, showing its effectiveness in preventing lesions in the gastrointestinal tract and promoting healing in various wounds. The peptide also demonstrates stability and protective effects against alcohol-induced damage and other harmful agents.
Inflammopharmacology· Sikiric P, Seiwerth S et al.
PubMed · PMID 17186181 ↗Animal study· ratmedium
2006
An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157.
This study found that BPC-157, a gastric pentadecapeptide, can recover esophagitis and sphincter failure in a rat model. The treatment also improved pressure in both the lower esophageal and pyloric sphincters.
Journal of pharmacological sciences· Petrovic I, Dobric I et al.
PubMed · PMID 17116974 ↗Animal study· ratmedium
2006
Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157.
The study found that BPC-157, a gastric pentadecapeptide, accelerates the healing of transected quadriceps muscle in rats, improving biomechanical, functional, and microscopic outcomes. The peptide consistently improved muscle healing throughout the 72-day study period.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society· Staresinic M, Petrovic I et al.
PubMed · PMID 16609979 ↗Animal study· ratmedium
2006
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation.
The peptide BPC-157 was shown to improve tendon-to-bone healing in rats with Achilles tendon detachment, and also reduced the aggravating effects of corticosteroids on healing. This suggests that BPC-157 may be a useful treatment for promoting tendon and bone healing.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society· Krivic A, Anic T et al.
PubMed · PMID 16583442 ↗Animal study· mousemedium
2006
The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine.
BPC-157 was shown to rapidly oppose the strongest disturbance presentations in acute alcohol intoxication and withdrawal in mice. The peptide's effects interacted with the NO-system, with L-arginine and L-NAME having distinctive effects on acute intoxication and withdrawal.
Medical science monitor : international medical journal of experimental and clinical research· Boban-Blagaic A, Blagaic V et al.
PubMed · PMID 16369461 ↗Animal study· ratmedium
2005
Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats.
The study found that BPC-157 accelerated the healing of corneal epithelial defects in rats, with a dose-dependent effect. Lesions in treated eyes disappeared faster than in control eyes.
Collegium antropologicum· Lazić R, Gabrić N et al.
PubMed · PMID 16117343 ↗Animal study· ratmedium
2005
Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats.
The study found that BPC-157, a gastric pentadecapeptide, reduced the duration and severity of serotonin syndrome in rats. The peptide showed a beneficial effect, particularly in counteracting 5-HT2A receptors phenomena, even at lower doses.
European journal of pharmacology· Boban Blagaic A, Blagaic V et al.
PubMed · PMID 15840402 ↗Animal study· mousemedium
2005
The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice.
The stable gastric pentadecapeptide BPC 157 improved healing of CO2 laser injuries in mice, both macroscopically and microscopically, when applied topically. The peptide was effective at various doses and with a simple method of application.
Burns : journal of the International Society for Burn Injuries· Bilic M, Bumber Z et al.
PubMed · PMID 15774286 ↗Animal study· ratmedium
2004
Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements.
This study found that BPC-157, a gut peptide, influences brain serotonin synthesis in rats, with both increases and decreases in synthesis rates observed in different brain regions. The exact mechanism of this action is not determined.
Life sciences· Tohyama Y, Sikirić P et al.
PubMed · PMID 15531385 ↗Animal study· mousemedium
2004
The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice.
BPC-157 protected against acute and chronic alcohol-induced lesions in the stomach and liver, and also reduced the effects of alcohol withdrawal in mice. The peptide was effective when given before or after ethanol administration, and also after abrupt cessation of ethanol.
European journal of pharmacology· Blagaic AB, Blagaic V et al.
PubMed · PMID 15381050 ↗Animal study· rat, mousemedium
2004
Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.
This study found that BPC-157, along with other treatments, can reverse or ameliorate doxorubicine-induced congestive heart failure in rats and mice by reducing big endothelin-1 plasma concentration and improving clinical status. BPC-157 also reduced plasma enzyme levels and improved clinical status in these animals.
Journal of pharmacological sciences· Lovric-Bencic M, Sikiric P et al.
PubMed · PMID 15153646 ↗Animal study· ratmedium
2004
Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.
BPC-157, administered intramuscularly or intragastrically, was shown to reduce the area of gastric ulcers and accelerate healing in rats, with intramuscular administration being more effective. The peptide also promoted rebuilding of glandular epithelium and formation of granulation tissue in chronic ulcers.
World journal of gastroenterology· Xue XC, Wu YJ et al.
PubMed · PMID 15052688 ↗Animal study· ratmedium
2003
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
The study found that BPC-157 accelerated healing of transected rat Achilles tendon and stimulated tendocyte growth in vitro. The peptide improved recovery by increasing load of failure, functional index, and promoting collagen formation.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society· Staresinic M, Sebecic B et al.
PubMed · PMID 14554208 ↗Animal study· ratmedium
2003
Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy.
The study found that BPC-157 had a cytoprotective effect on cysteamine-induced duodenal ulcers in rats, even after sialoadenectomy, whereas other antiulcer agents were ineffective. This suggests that BPC-157 has a unique mechanism of action that is distinct from other antiulcer agents.
European journal of pharmacology· Bedekovic V, Mise S et al.
PubMed · PMID 14512101 ↗Animal study· mousemedium
2003
Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice.
This study found that BPC-157 cream improved burn healing and counteracted the negative effects of corticosteroids on healing in mice. BPC-157 also showed an anti-ulcer effect and inhibited corticosteroid immunosuppression.
Burns : journal of the International Society for Burn Injuries· Sikiric P, Seiwerth S et al.
PubMed · PMID 12781609 ↗Animal study· ratmedium
2002
Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.
The peptide BPC-157 attenuated chronic amphetamine-induced behavioral disturbances in rats, including stereotyped behavior and heightened startle response. This effect was present throughout the observation period at a statistically significant level.
Acta pharmacologica Sinica· Sikiric P, Jelovac N et al.
PubMed · PMID 11978191 ↗Animal study· rat, mousemedium
2001
Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test.
BPC-157, a gastric pentadecapeptide, showed an anxiolytic effect in rats and mice, similar to diazepam, but with distinct behavioral differences. The study suggests that BPC-157 may have a unique mechanism of action compared to traditional anxiolytics.
Acta pharmacologica Sinica· Sikiric P, Jelovac N et al.
PubMed · PMID 11742568 ↗Animal study· mousemedium
2001
Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice.
BPC-157 cream improved burn-wound healing and reduced gastric lesions in mice, with benefits including increased collagen formation, reduced edema, and improved skin strength. The peptide also attenuated burn-induced gastric lesions when administered topically or systemically.
Burns : journal of the International Society for Burn Injuries· Mikus D, Sikiric P et al.
PubMed · PMID 11718984 ↗Animal study· ratmedium
2001
Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.
The stable gastric pentadecapeptide BPC 157 was shown to prevent and reverse portal hypertension and liver lesions in rats with chronic alcohol-induced liver damage. BPC 157 had a beneficial effect on liver health, reducing portal pressure and improving liver morphology.
Journal of physiology, Paris· Prkacin I, Separovic J et al.
PubMed · PMID 11595456 ↗Animal study· ratmedium
2001
Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats.
The study found that BPC-157, ranitidine, omeprazole, and atropine had a beneficial effect on lung lesions in rats, and that combining prophylactic and therapeutic regimens of these agents attenuated lung lesions. The agents also reduced the severity of gastric lesions caused by ethanol instillation.
Journal of physiology, Paris· Stancic-Rokotov D, Slobodnjak Z et al.
PubMed · PMID 11595454 ↗Animal study· ratmedium
2001
Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.
The pentadecapeptide BPC 157, ranitidine, and propranolol were found to prevent, attenuate, or reverse gastric lesions in chronically alcohol-drinking rats. These substances may be used for further therapy in treating gastric lesions related to alcohol consumption.
Journal of physiology, Paris· Prkacin I, Aralica G et al.
PubMed · PMID 11595453 ↗Animal study· ratmedium
2001
Ethanol gastric lesion aggravated by lung injury in rat. Therapy effect of antiulcer agents.
This study found that antiulcer agents, including BPC-157, can protect against ethanol-induced gastric lesions in rats, even in the presence of severe lung injury. The combination of prophylactic and therapeutic regimens of these agents may increase their antiulcer potential.
Journal of physiology, Paris· Stancic-Rokotov D, Sikiric P et al.
PubMed · PMID 11595452 ↗Animal study· ratmedium
2001
Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat.
The study found that pentadecapeptide BPC 157, along with other antiulcer agents, mitigated and reversed colon lesions in rats caused by cysteamine. BPC 157 also prevented the reappearance of lesions after stopping therapy.
Journal of physiology, Paris· Sikiric P, Seiwerth S et al.
PubMed · PMID 11595451 ↗Animal study· ratmedium
2001
Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone.
The study found that the peptide BPC-157, as well as other antiulcer agents, can attenuate cysteamine-induced colon and duodenal lesions in rats. This suggests a potential protective effect of these agents against gastrointestinal damage.
Journal of physiology, Paris· Sikiric P, Seiwerth S et al.
PubMed · PMID 11595448 ↗Animal study· mousemedium
2001
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
The peptide BPC-157, along with omeprazole and bromocriptine, was found to attenuate stomach lesions caused by haloperidol in mice, while other antiulcer agents were not effective. The effectiveness of BPC-157 was reduced when prostaglandin synthesis was blocked.
Life sciences· Bilic I, Zoricic I et al.
PubMed · PMID 11292068 ↗Animal study· ratmedium
2000
Gastric mucosal lesions induced by complete dopamine system failure in rats. The effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157.
The study found that pentadecapeptide BPC 157, along with other agents like ranitidine and omeprazole, prevented gastric lesions in rats induced by dopamine system failure. These agents maintained their beneficial effects even when the dopamine system was extensively inhibited.
Journal of physiology, Paris· Sikiric P, Separovic J et al.
PubMed · PMID 10791690 ↗Animal study· ratmedium
2000
The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants.
The peptide BPC-157 showed antidepressant effects in rats, comparable to conventional antidepressants, in both a forced swimming test and a chronic unpredictable stress procedure. BPC-157's effectiveness was not delayed, unlike some conventional antidepressants, and was present even under severe experimental conditions.
Journal of physiology, Paris· Sikiric P, Separovic J et al.
PubMed · PMID 10791689 ↗Animal study· mousemedium
1999
The effect of a novel pentadecapeptide BPC 157 on development of tolerance and physical dependence following repeated administration of diazepam.
This study found that BPC-157, when co-administered with diazepam, attenuated diazepam tolerance and postponed physical dependence/withdrawal effects in mice. The results suggest that BPC-157 may have a mechanism that favors the natural homeostasis of the GABA receptor complex and enhances GABAergic transmission.
The Chinese journal of physiology· Jelovac N, Sikiric P et al.
PubMed · PMID 10707891 ↗Animal study· mousemedium
1999
A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.
BPC-157 improved symptoms of Parkinson's disease in mice and reduced stomach lesions caused by a neurotoxin. The peptide also prevented and reversed catalepsy and hypothermia in mice treated with reserpine.
Journal of physiology, Paris· Sikiric P, Marovic A et al.
PubMed · PMID 10672997 ↗Animal study· rat, mousemedium
1999
Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.
The pentadecapeptide BPC 157 was found to attenuate gastric lesions induced by alloxan in rats and mice. This beneficial effect was observed at both microgram and nanogram doses.
Journal of physiology, Paris· Petek M, Sikiric P et al.
PubMed · PMID 10672996 ↗Animal study· ratmedium
1999
The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation.
The study found that BPC-157, along with other gastroprotective agents, increased the formation of new blood vessels and granulation tissue in rats. BPC-157 was particularly effective in stimulating granulation tissue formation, similar to sucralfate.
Journal of physiology, Paris· Sikiric P, Separovic J et al.
PubMed · PMID 10672992 ↗Animal study· ratmedium
1999
Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats.
The study found that BPC-157 provided long-lasting cytoprotection against reflux oesophagitis in rats, outperforming other anti-ulcer agents like ranitidine, sucralfate, and cholestyramine. This suggests that BPC-157 may be a useful therapy for resistant reflux oesophagitis conditions.
Journal of physiology, Paris· Sikiric P, Jadrijevic S et al.
PubMed · PMID 10672991 ↗Animal study· mouse, ratmedium
1999
Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
BPC-157 was found to attenuate catalepsy and gastric ulcers in mice and rats induced by neuroleptics, suggesting its potential protective effects on the dopamine system and gastrointestinal tract. The peptide was shown to reduce catalepsy and somatosensory disorientation in mice and prevent gastric ulcers in rats when coadministered with neuroleptics.
European journal of pharmacology· Jelovac N, Sikiric P et al.
PubMed · PMID 10499368 ↗Animal study· rabbitmedium
1999
Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation.
The study found that the peptide BPC-157 significantly improved the healing of segmental bone defects in rabbits, with effects comparable to those of bone marrow and autologous cortical bone implantation. The peptide was effective when administered locally or intramuscularly, and showed promise for potential use in human bone healing.
Bone· Sebecić B, Nikolić V et al.
PubMed · PMID 10071911 ↗Animal study· ratmedium
1999
New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin.
This study introduced a new model of cytoprotection and adaptive cytoprotection in rats, and found that pentadecapeptide BPC 157 had mainly adaptive cytoprotective activity. The study suggests that BPC 157 and other agents can function as a link between various reactions in cytoprotection and adaptive cytoprotection.
European journal of pharmacology· Sikirić P, Seiwerth S et al.
PubMed · PMID 9920181 ↗Animal study· rat, mousemedium
1998
A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.
BPC-157, a gastric pentadecapeptide, was found to block stereotypy produced by amphetamine and prevent the development of haloperidol-induced supersensitivity to amphetamine in rats and mice. This suggests an interaction between BPC-157 and the dopamine system.
Biological psychiatry· Jelovac N, Sikirić P et al.
PubMed · PMID 9547930 ↗Animal study· ratmedium
1997
The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure.
BPC-157 had an antiulcer effect and helped maintain blood pressure in rats, and its effects on gastric mucosal integrity and blood pressure maintenance were distinct from those of nitric oxide and L-arginine. BPC-157 also induced nitric oxide generation in gastric mucosa, but its effect was not inhibited by L-NAME.
European journal of pharmacology· Sikirić P, Seiwerth S et al.
PubMed · PMID 9298922 ↗Animal study· ratmedium
1997
BPC 157's effect on healing.
BPC 157 was found to promote the healing process in rat models of skin incisional wounds, colon-colon anastomoses, and angiogenesis. The peptide showed a strong, promoting involvement in the healing process, including granulation tissue and collagen formation, angiogenesis, and tensile strength development.
Journal of physiology, Paris· Seiwerth S, Sikiric P et al.
PubMed · PMID 9403790 ↗Animal study· chickmedium
1997
The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks.
The peptide BPC 157 was shown to prevent pulmonary hypertension syndrome and tissue damage in chicks when administered with L-arginine, and it did not cause any tissue or organ damage on its own. BPC 157 also inhibited the negative effects of the nitric oxide antagonist L-NAME.
Journal of physiology, Paris· Grabarevic Z, Tisljar M et al.
PubMed · PMID 9403788 ↗Animal study· ratmedium
1997
Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats.
BPC-157 reduced gastrointestinal lesions caused by non-steroidal anti-inflammatory agents and also reduced the development of adjuvant arthritis in rats. The peptide showed a protective effect on mucosal integrity and an anti-inflammatory effect.
Journal of physiology, Paris· Sikiric P, Seiwerth S et al.
PubMed · PMID 9403784 ↗Animal study· ratmedium
1997
Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies.
The study found that BPC-157, a pentadecapeptide, had a cytoprotective effect in preventing duodenal lesions in rats, and this effect was independent of stomach acid. The peptide was compared to other reference agents and showed similar protective effects.
Digestive diseases and sciences· Sikirić P, Mikus D et al.
PubMed · PMID 9149058 ↗Animal study· ratmedium
1997
Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress.
This study found that BPC 157 interacts with adrenergic and dopaminergic systems to provide gastroprotection in stressed animals, and that its effects can be influenced by various agents that affect these systems. The study suggests a complex protective interaction between BPC 157 and both alpha-adrenergic and dopaminergic systems.
Digestive diseases and sciences· Sikirić P, Mazul B et al.
PubMed · PMID 9073154 ↗Animal study· ratmedium
1997
Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats.
BPC-157 pretreatment was found to prevent mastocyte infiltration and reduce polymorphonuclear leukocyte infiltration in a rat model of capsaicin-induced rhinitis. The effect of BPC-157 was dose-dependent for polymorphonuclear leukocyte infiltration at 12 hours.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery· Kalogjera L, Ries M et al.
PubMed · PMID 9065615 ↗Animal study· ratmedium
1996
Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity.
The pentadecapeptide BPC 157 was shown to have a beneficial effect on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity in rats. The protection provided by BPC 157 was still evident in capsaicin-treated rats, but its effectiveness was influenced by the dose and timing of capsaicin administration.
Digestive diseases and sciences· Sikirić P, Seiwerth S et al.
PubMed · PMID 8769287 ↗Animal study· ratmedium
1996
Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats.
BPC-157 showed a protective effect on acute pancreatitis and concomitant gastroduodenal lesions in rats when given prophylactically or therapeutically. The peptide reduced necrosis, edema, and neutrophils, and had a positive influence on serum amylase values.
Digestive diseases and sciences· Sikirić P, Seiwerth S et al.
PubMed · PMID 8689934 ↗Animal study· ratmedium
1994
The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides.
BPC-157, a 15 amino acid peptide, demonstrated protective effects on gastric and duodenal lesions in rats, outperforming other reference standards in three experimental ulcer models. The peptide's beneficial effect appears to be related to strong endothelial protection.
Life sciences· Sikiric P, Seiwerth S et al.
PubMed · PMID 7904712 ↗Animal study· ratmedium
1993
Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.
BPC-157, a 15-amino acid peptide, showed hepatoprotective effects in rats with liver lesions induced by various methods, outperforming reference drugs like dopamine agonists and somatostatin. The peptide prevented liver necrosis and fatty changes, with laboratory test results correlating with macro/microscopical findings.
Life sciences· Sikiric P, Seiwerth S et al.
PubMed · PMID 7901724 ↗Animal study· ratmedium
1992
The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures.
The study found that the gastroprotective effect of Body Protection Compound (BPC) was modulated by various procedures such as ovariectomy, demedullation, and thyroparathyroidectomy, suggesting a complex and sex-related action. The results also imply that gastroprotection is a crucial pattern in the general concept of organoprotection.
Acta physiologica Hungarica· Sikiric P, Petek M et al.
PubMed · PMID 1345210 ↗From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.
BPC-157, a synthetic peptide, has shown promise in preclinical models for tissue repair and pain management, with potential therapeutic value for various conditions, but human research is limited and more rigorous trials are needed. The review concludes that BPC-157 is a promising candidate for regenerative medicine, but comprehensive evaluation is required before clinical translation can be recommended.
International journal of molecular sciences· Yuan C, Demers A et al.
PubMed · PMID 41898733 ↗Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias.
This review suggests that BPC 157 may have cytoprotective and antiarrhythmic effects, and proposes its potential use as a therapeutic agent for arrhythmias. The review concludes that BPC 157 demonstrates full cytoprotection and wide-range homeostasis in preclinical models.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Barisic I et al.
PubMed · PMID 41754776 ↗Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
This review of injectable peptide therapy found that while BPC-157 and other peptides show potential for tissue repair and regenerative medicine, there is a lack of evidence to support their clinical use, particularly in human trials. The review concludes that more research is needed to determine the safety and efficacy of these peptides.
The American journal of sports medicine· Mayfield CK, Bolia IK et al.
PubMed · PMID 41476424 ↗Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185".
This paper is a response to a comment on a previous manuscript about BPC-157, and does not present new research findings. The authors acknowledge the comment and express their gratitude for the interest in their work.
Pharmaceuticals (Basel, Switzerland)· Józwiak M, Bauer M et al.
PubMed · PMID 41155566 ↗Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, but human data is extremely limited, with only three pilot studies conducted. The review concludes that BPC-157 should be considered investigational and its use approached with caution until well-designed clinical trials are conducted.
Current reviews in musculoskeletal medicine· McGuire FP, Martinez R et al.
PubMed · PMID 40789979 ↗Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).
This article discusses a review of BPC-157's role as a cytoprotectant in protecting the gastrointestinal tract. The review concludes that BPC-157 has potential protective effects on the GIT.
Inflammopharmacology· Whitehouse M
PubMed · PMID 40759852 ↗Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
This systematic review suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries, with preclinical studies showing improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries. However, the review highlights the need for further clinical safety data and notes that adverse effects are possible due to unregulated manufacturing or contamination.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery· Vasireddi N, Hahamyan H et al.
PubMed · PMID 40756949 ↗Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.
This review discusses the limitations of current pharmacotherapies for abdominal compartment syndrome and intra-abdominal hypertension, and highlights the potential benefits of BPC-157 therapy in resolving these conditions. BPC-157 is proposed as a novel cytoprotective mediator with pleiotropic beneficial effects.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Seiwerth S et al.
PubMed · PMID 40573261 ↗Human trial· humanlow
2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
This pilot study found that intravenous infusion of BPC-157 in two healthy adults showed no adverse effects and was well-tolerated. The study assessed the safety of BPC-157 in humans, but more research is needed to confirm these findings.
Alternative therapies in health and medicine· Lee E, Burgess K
PubMed · PMID 40131143 ↗Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
This review summarizes the biological activities of BPC 157, a peptide with potential therapeutic benefits for various medical conditions, including tissue injury and inflammatory bowel disease. The review highlights the need for comprehensive clinical studies to confirm its health benefits in humans.
Pharmaceuticals (Basel, Switzerland)· Józwiak M, Bauer M et al.
PubMed · PMID 40005999 ↗Withdrawn: Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.
This paper was withdrawn at the author's request and does not contain any findings. The original topic was the use of BPC-157 as a therapy for severe electrolyte disturbances in rats.
Current neuropharmacology· Grubisic MM, Strbe S et al.
PubMed · PMID 39865815 ↗Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?
This review discusses the potential of injectable peptides, including BPC-157, in treating joint injuries and osteoarthritis, and highlights the need for further research on their clinical use and outcomes. The review notes that despite limited orthopaedic literature, the use of therapeutic peptides is growing rapidly.
Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association· DeFoor MT, Dekker TJ
PubMed · PMID 39265666 ↗Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.
This review discusses the use of BPC-157 therapy in healing various intestinal anastomoses and fistulas in rats, suggesting its potential in treating gastrointestinal tract injuries. The review concludes that BPC-157 therapy may be an effective approach in promoting the healing of distinctive anastomoses and fistulas.
Pharmaceuticals (Basel, Switzerland)· Bajramagic S, Sever M et al.
PubMed · PMID 39204186 ↗New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.
This review discusses the potential of BPC-157 as a mediator of cytoprotection and organoprotection, and its possible applications in various therapeutic areas, including gastrointestinal health and tissue healing. The review highlights the peptide's ability to counteract vascular and multiorgan failure in occlusion/occlusion-like syndromes.
Inflammopharmacology· Sikiric P, Sever M et al.
PubMed · PMID 38980576 ↗The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.
This review highlights the potential beneficial effects of BPC-157, a stable gastric pentadecapeptide, and its possible relations with neurotransmitter activity, including counteracting disturbances in dopamine, serotonin, and other neurotransmitter systems. The review suggests that BPC-157 may have therapeutic applications in various conditions, including muscle and nerve disturbances.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Boban Blagaic A et al.
PubMed · PMID 38675421 ↗Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.
This study used a stable isotope labeling-based nontargeted strategy to characterize the in vitro metabolic profile of BPC-157, discovering one novel metabolic pathway and eight conventional metabolites. A detection method for BPC-157 and its main metabolites in human urine was also developed and validated.
Molecules (Basel, Switzerland)· Tian T, Jing J et al.
PubMed · PMID 37959764 ↗Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function.
This review suggests that BPC-157 may have a beneficial effect on the brain-gut and gut-brain axes, and may be useful in treating various conditions, including muscle and gut disorders, as well as mental health issues. The review concludes that BPC-157 therapy may have a wide range of beneficial effects, both peripherally and centrally.
Pharmaceuticals (Basel, Switzerland)· Sikiric P, Gojkovic S et al.
PubMed · PMID 37242459 ↗Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways.
This editorial discusses the potential of BPC-157 to activate collateral pathways. The specifics of the activation are not provided in the abstract.
Current medicinal chemistry· Sikiric P, Gojkovic S et al.
PubMed · PMID 36200148 ↗Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle.
This review concludes that BPC-157 therapy may promote healing of various tissues, including muscle, tendon, and bone, and may also have potential in treating muscle disabilities and heart and smooth muscle dysfunction. The review suggests that BPC-157 has a wide range of potential therapeutic applications due to its cytoprotective properties.
Biomedicines· Staresinic M, Japjec M et al.
PubMed · PMID 36551977 ↗Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation.
This review discusses the potential therapeutic effects of BPC-157 in treating heart disturbances, including myocardial infarction, heart failure, and arrhythmias, by exerting cytoprotective and cardioprotective effects. The peptide may also have modulatory effects on various molecular pathways, including the NO-system and prostaglandins system.
Biomedicines· Sikiric P, Udovicic M et al.
PubMed · PMID 36359218 ↗Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome.
This review summarizes the evidence for the cytoprotective effects of BPC-157, a stable gastric pentadecapeptide, in resolving major vessel occlusion disturbances and ischemia-reperfusion injury. The review concludes that BPC-157 has profound cytoprotective activity and may be useful in various therapeutic applications.
World journal of gastroenterology· Sikiric P, Skrtic A et al.
PubMed · PMID 35125818 ↗Corrigendum: Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats.
This paper is a corrigendum to a previous article and does not present new findings. The original article likely investigated the use of BPC-157 in treating primary abdominal compartment syndrome in rats.
Frontiers in pharmacology· Tepes M, Gojkovic S et al.
PubMed · PMID 35126157 ↗BPC 157 as Potential Treatment for COVID-19.
This paper discusses the potential of BPC-157 as a treatment for COVID-19 based on its anti-inflammatory, cytoprotective, and endothelial-protective effects. The authors suggest that BPC-157 may improve clinical management of COVID-19, but note that further research is needed.
Medical hypotheses· Deek SA
PubMed · PMID 34798584 ↗Case report· humanlow
2021
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
This study found that intra-articular injection of BPC-157 helped relieve knee pain in 87.5% of patients with various types of knee pain. The study suggests that BPC-157 may be a useful treatment for multiple types of knee pain.
Alternative therapies in health and medicine· Lee E, Padgett B
PubMed · PMID 34324435 ↗BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection.
This review article discusses the potential of BPC 157 to rescue NSAID-induced cytotoxicity by stabilizing intestinal permeability and enhancing cytoprotection. It concludes that BPC 157 may be a possible way to secure GI safety against NSAIDs-induced gastroenteropathy.
Current pharmaceutical design· Park JM, Lee HJ et al.
PubMed · PMID 32445447 ↗Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.
This review discusses the potential of BPC-157 in healing fistulas and promoting gastrointestinal health, citing its effectiveness in various wound types and its potential as a novel mediator of cytoprotection. The review highlights the consistent healing of gastrointestinal fistulas in rats treated with BPC-157.
Current pharmaceutical design· Sikiric P, Drmic D et al.
PubMed · PMID 32329684 ↗Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.
This review discusses the potential benefits of BPC-157 in protecting the stomach and other organs from damage, and its possible role in wound healing and stress response. The authors conclude that BPC-157 may have therapeutic potential in various conditions, including gastrointestinal disorders and cancer cachexia.
Gut and liver· Sikiric P, Hahm KB et al.
PubMed · PMID 31158953 ↗Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
This review concludes that BPC-157 has shown consistently positive and prompt healing effects for various soft tissue injuries in animal models, but its efficacy in humans is yet to be confirmed. The peptide has potential as a therapy for conservatively treating or aiding recovery in hypovascular and hypocellular soft tissues.
Cell and tissue research· Gwyer D, Wragg NM et al.
PubMed · PMID 30915550 ↗Mechanistic· cell-linelow
2019
Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells.
This study investigated the cytoprotective mechanism of BPC-157 in the gastrointestinal tract and found that it has a protective effect on cultured enteric neurons and glial cells. The exact mechanisms of this effect are not specified in the abstract.
Neuroscience bulletin· Wang XY, Qu M et al.
PubMed · PMID 30116973 ↗In vitro· cell-linelow
2018
Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities.
This study showed that Lactococcus lactis can be engineered to deliver BPC-157 peptide, which can decrease reactive oxygen species production in a fibroblast cell model, suggesting potential benefits in treating intestinal inflammations. The most effective delivery approach was found to be secretion via the Usp45 signal.
Applied microbiology and biotechnology· Škrlec K, Ručman R et al.
PubMed · PMID 30191288 ↗BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.
This review concludes that BPC-157 is consistently effective in healing various tissues, including the gastrointestinal tract, tendon, ligament, and bone, and may represent a pharmacological and pathophysiological role of various peptidergic growth factors. BPC-157 was found to be effective in all models of acute and chronic injury, unlike other growth factors which had limited or inconsistent effects.
Current pharmaceutical design· Seiwerth S, Rucman R et al.
PubMed · PMID 29998800 ↗BPC157 as Potential Agent Rescuing from Cancer Cachexia.
This review proposes the potential application of BPC157 for cancer cachexia and discusses its possible mode of action. The authors suggest that BPC157 could be a useful agent in rescuing patients from cancer cachexia, but note that clinical trials are needed to confirm this.
Current pharmaceutical design· Kang EA, Han YM et al.
PubMed · PMID 29898649 ↗Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.
This review discusses the cytoprotective effects of BPC-157, a stable gastric pentadecapeptide, and its potential to heal various organ lesions, including those in the gastrointestinal tract. BPC-157 is shown to provide endothelium protection and promote blood vessel function, leading to improved healing and recovery.
Current pharmaceutical design· Sikiric P, Rucman R et al.
PubMed · PMID 29879879 ↗Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
This review discusses the potential of BPC-157 as an integrative mediator that integrates the adaptive bodily response to stress, with beneficial effects on various tissues and organs. It concludes that BPC-157 may be a solution for stress-related disorders, particularly in the gastrointestinal tract.
Current pharmaceutical design· Sikiric P, Seiwerth S et al.
PubMed · PMID 28228068 ↗Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.
This study developed a method to detect BPC 157 in urine and found that it forms a stable metabolite. The method has a limit of detection of 0.1 ng/mL and is stable in urine for at least 4 days.
Drug testing and analysis· Cox HD, Miller GD et al.
PubMed · PMID 28035768 ↗BPC 157 and blood vessels.
This review concludes that BPC 157 is a potent angiomodulatory agent that optimizes vascular response and healing processes through various vasoactive pathways. It discusses the role of BPC 157 in different aspects of vascular response to injury, including endothelium damage, clotting, and thrombosis.
Current pharmaceutical design· Seiwerth S, Brcic L et al.
PubMed · PMID 23782145 ↗Stable gastric pentadecapeptide BPC 157-NO-system relation.
This review discusses the relationship between the peptide BPC-157 and the nitric oxide (NO) system, and how BPC-157 may promote healing in various tissues. The review concludes that BPC-157 has a beneficial effect on healing and NO-system regulation, but the clinical implications of this relationship are not yet clear.
Current pharmaceutical design· Sikiric P, Seiwerth S et al.
PubMed · PMID 23755725 ↗Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157.
This review suggests that BPC-157 may be used as an antidote against NSAIDs due to its beneficial effects on stomach, duodenum, intestine, liver, and brain injuries. BPC-157 has a high safety profile with no reported toxicity.
Current pharmaceutical design· Sikiric P, Seiwerth S et al.
PubMed · PMID 22950504 ↗Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.
This review discusses the potential of BPC-157 as a new drug for treating inflammatory bowel disease (IBD), including ulcerative colitis, due to its antiulcer effect, wound healing properties, and interaction with the NO-system. The review concludes that BPC-157 may be a significant therapy for IBD due to its safe profile and potential to counteract severe complications.
Current medicinal chemistry· Sikiric P, Seiwerth S et al.
PubMed · PMID 22300085 ↗Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator.
This review discusses the potential role of BPC-157 in cytoprotection and adaptive cytoprotection, suggesting it may be an essential mediator for stomach and gastrointestinal tract defense, with implications for wound healing. The review highlights BPC-157's safety and efficacy in clinical trials for inflammatory bowel disease and wound healing.
Current pharmaceutical design· Sikiric P, Seiwerth S et al.
PubMed · PMID 20166993 ↗The pharmacological properties of the novel peptide BPC 157 (PL-10).
This review discusses the potential beneficial effects of BPC-157 on various organ lesions, including gastrointestinal, pancreas, liver, and heart damage, as well as its potential role in a peptidergic defence system. The review concludes that BPC-157 may be a new physiological defence system that warrants further investigation.
Inflammopharmacology· Sikiric P
PubMed · PMID 17657443 ↗Direct cellular effects of some mediators, hormones and growth factor-like agents on denervated (isolated) rat gastric mucosal cells.
This study found that PL-10 substances, which are synthesized parts of BPC, had a direct cytoprotective effect on isolated rat gastric mucosal cells, protecting them against ethanol-induced damage. The study suggests that growth factor-like agents have a direct cellular effect on gastric cytoprotection.
Journal of physiology, Paris· Bódis B, Karádi O et al.
PubMed · PMID 9403792 ↗Ex vivo· rat, mouselow
1997
Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound, BPC) and their specificity to gastric mucosal cells.
This study found that certain synthesized parts of the body protection compound (BPC) had a direct protective effect on gastric mucosal cells against ethanol-induced damage. The protective effect was specific to gastric mucosal cells and not observed in mouse myeloma cells.
Life sciences· Bódis B, Karádi O et al.
PubMed · PMID 9353174 ↗A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC.
This review proposes the 'stomach-stress-organoprotection hypothesis' and discusses the potential benefits of a newly isolated gastric juice peptide, BPC, and its fragment BPC 157, in protecting organs from stress-related damage. The review suggests that BPC 157 may have therapeutic potential as an organoprotective agent.
Journal of physiology, Paris· Sikirić P, Petek M et al.
PubMed · PMID 8298609 ↗